Compare Organon & Co. Common Stock (OGN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tyson Foods, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Tyson Foods, Inc. trades at $54.5 (market cap $18.92B). The key difference: Tyson Foods, Inc. is far larger — about 5.2× Organon & Co. Common Stock's market cap, and Tyson Foods, Inc. pays the higher dividend (3.79%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tyson Foods, Inc. for 77 Days on average.
| OGN | TSN | |
|---|---|---|
Market Cap | $3.62B | $18.92B |
Volume | 2,892,999 | 2,968,585 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $68.75 |
52-Week Low | $5.70 | $50.47 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.04B | $26.19B |
Dividend Yield | 0.58% | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Tyson Foods (TSN) trades at $54.22, up 1.21% with a bullish technical signal despite recent volatility. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining a 53% analyst buy rating. Current valuation metrics include a P/E of 33.2 and P/S of 0.34, with revenue growth projected to $55.7B in 2026. Recent corporate actions include consistent dividend payments of $0.51 per share.
Outlook remains cautiously optimistic with a $65.40 consensus price target representing 21% upside potential. Key risks include ongoing beef segment losses, securities investigations, and margin pressure. The company's ability to maintain dividends while addressing operational challenges will be critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
